Manifestaciones cutáneas de las enfermedades reumatológicas

  1. Polo Rodríguez, I.
  2. Medina Montalvo, S.
  3. Trasobares Marugán, L.
  4. Bohórquez Heras, C.
Revista:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Año de publicación: 2017

Título del ejemplar: Enfermedades del sistema inmune y reumatológicas (III) Espondiloartritis. Manifestaciones cutáneas de las enfermedades reumatológicas

Serie: 12

Número: 26

Páginas: 1520-1529

Tipo: Artículo

DOI: 10.1016/J.MED.2017.01.013 DIALNET GOOGLE SCHOLAR

Otras publicaciones en: Medicine: Programa de Formación Médica Continuada Acreditado

Objetivos de desarrollo sostenible

Resumen

Introduction Connective tissue is widely distributed all over the organism, being part of the skin and its annexes and of the joints. Rheumatic diseases produce swelling as a consequence of autoimmune mechanisms of that connective tissue (connective tissue diseases). Skin is an important target organ of these diseases. Their manifestations are, usually, the first sign to guide the diagnosis. Dermatologic lesions associated to connective tissue disease Throughout the text the characteristics of the following diseases and lesions are outlined. Diseases related to photosensitivity: lupus erythematosus and dermatomyositis; sclerotic lesions: sclerodermia; Raynaud's syndrome; urticarial lesions: chronic urticaria, urticarial vasculitis, Still disease; subcutaneous nodular lesions: rheumatic nodules, subcutaneous nodules, polyarteritis nodosa; neutrophilic dermatoses; vasculitis; psoriasis; mucosal lesions: aphthous ulcers and Behçet's disease. Clinical manifestations on the skin are very diverse. Conclusion It is important to know the dermatological symptoms, given that early diagnosis and treatment onset can help prevent future complications and improve prognosis.

Referencias bibliográficas

  • Núñez Cuadros E, Téllez Labao C, Galindo Zabala R, Vera Castaño A. Alteraciones cutáneas con significación reumatológica. Protoc Diagn Ter Pediatr. 2014;1:241-61.
  • Fuhlbrigge RC1, Chaiban R. The immune system, the skin and chilhood. Curr Rheumatol Rep. 2011;13:103-9.
  • Kalus A. Rheumatologic skin disease. Med Clin N Am. 2015;99:1287-303.
  • Ciudad-Blanco C, Avilés Izquierdo JA, Campos-Domínguez M, Suárez-Fernández R, Lázaro Ochaita P. Dermatomiositis: estudio y seguimiento de 20 pacientes. Actas Dermosifiliogr. 2011;102:448-55.
  • Hornung T, Janzen V, Heidgen FJ. Remission of recalcitrant dermatomyositis treated with ruxolitinib. N Eng J Med. 2014;371(26):704-11.
  • Costner MI, Grau RH. Update on connective tissue diseases in dermaology. Semin Cutan Med Surg. 2006;25:207-20.
  • Brady SM, Shapiro L, Mousa SA. Current and future direction in the management of scleroderma. Arch Dermatol Res. En prensa 2016.
  • Capelli L, Wigley FM. Management of Raynaud phenomenon and digital ulcers in sclerodema. Rheum Dis Clin N Am. 2015;41:419-38.
  • Pavlov-Dolijanovic S, Damjanov NS, Vujasinovic Stupar NZ. Is there a difference in systemic lupus erytheatosus with and without Raynaud ́s phenomenon? Rheumatol Int. 2013;34(1):11-24.
  • Dobloug C, Garen T, Bitter H. Prevalence and clinical characteristics of adult polymyositis and dermatomyositis; data from a large and unselected Norwegian cohort. Ann Rheum Dis. 2015;74(8):1551-6.
  • Hughes M, Herrick AL. Raynaud ́s phenomenon. Best Pract Res Clin Rheumatol. 2016;30:112-32.
  • Zebryk P, Puszczewicz MJ. Botulinum toxin A in the treatment of Raynaud’s phenomenon: a systematic review. Arch Med Sci. 2016;12(4): 864-70.
  • Kolkhir P, Pogorelov D, Olisova O, Maurer M. Comorbidity and pathogenic links of chronic spontaneous urticaria and systemic lupus erythematosus- a systematic review. Clin Exp Allergy. 2016;46:275-87.
  • Moreno-Suárez F, Pulpillo-Ruiz Á, Zulueta Dorado T, Conejo-Mir Sánchez J. Urticarial vasculitis: a retrospective study of 15 cases. Actas Dermosifiliogr. 2013;104(7):579-85.
  • Yosifuku A, Kawai K, Kanekura T. Adult- onset Still disease with peculiar persistent plaques and papules. Clin Exp Dermatol. 2014;39:503-5.
  • Palencia Pérez SI, López Gómez S, Vanaclocha Sebastián F, Rodríguez Peralto JL, Iglesias Díez L. Paniculitis lúpica asociada a lupus eritematoso sistémico. Actas Dermosifiliogr. 2002;93:181-3.
  • Prat L, Bouaziz JD, Wallach D, Vignon-Pennamen MD, Bagot M. Neutrophilic dermatoses as systemic diseases. Clin Dermatol. 2014;32:376-88.
  • Gusdorf L, Bessis D, Lipsker D. Lupus erythematosus and neutrophilic urticarial dermatosis. A retrospective study of 7 patients. Medicine. 2014; 93(29):e351.
  • Pulido-Pérez A, Avilés-Izquierdo JA y Suárez-Fernández R. Vasculitis cutáneas. Actas Dermosifiliogr. 2012;103(3):179-91.
  • Napolitano M, Caso F, Scarpa R, Megna M, Patrì A, Balato N. Psoriatic arthritis and psoriasis: differential diagnosis. Clin Rheumatol. 2016;35(8):1893-901.
  • Puig L, Carrascosa JM, Carretero G. Directrices españolas basadas en la evidencia para el tratamiento de la psoriasis con agentes biológicos, 2013. I. Consideraciones de eficacia y selección del tratamiento. Actas Dermosifiliogr. 2013;104(8):694-709.
  • Alpsoy E. Behçet’s disease: A comprehensive review with a focus on epi-demiology, etiology and clinical features, and management of mucocutaneous lesions. J Dermatol. 2016;43:620-32.
Fuente de los datos: Dialnet